Literature DB >> 2630352

Morphological effects of argon laser trabeculoplasty upon the glaucomatous human meshwork.

R A Alexander1, I Grierson.   

Abstract

Thirty four trabeculectomy specimens from open angle glaucoma patients who had under argon laser trabeculoplasty as part of their treatment, were studied by scanning electron microscopy. Three of these were also examined by transmission electron microscopy. The intervals between laser therapy and surgery ranged from one month to five years. A sub-group consisted of six patients who had received laser treatment on more than one occasion prior to surgery. Electron microscopy revealed distortion of trabecular beams, loss of trabecular endothelial cells and the development of a cellular sheet extending from the region of Schwalbe's line and covering the anterior surfaces of the anterior portion of the uveal meshwork. The sheet occluded the trabecular spaces of the region; thus, when extensive, contributing to laser trabeculoplasty failure. It is concluded that argon laser trabeculoplasty induces a repair process, in the form of repopulating a cellular deficient meshwork, but which can become detrimental as a consequence of its success.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2630352     DOI: 10.1038/eye.1989.111

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  18 in total

1.  Membrane formation in the chamber angle after failure of argon laser trabeculoplasty: analysis of risk factors.

Authors:  T Koller; J Stürmer; C Remé; B Gloor
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Immediate intraocular pressure response to selective laser trabeculoplasty.

Authors:  P Lanzetta; U Menchini; G Virgili
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

Review 3.  Stemming vision loss with stem cells.

Authors:  Valentina Marchetti; Tim U Krohne; David F Friedlander; Martin Friedlander
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

4.  A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma.

Authors:  M Nagar; A Ogunyomade; D P S O'Brart; F Howes; J Marshall
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

5.  Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial.

Authors:  W G Hodge; K F Damji; W Rock; R Buhrmann; A M Bovell; Y Pan
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

Review 6.  Advances in treatment and management: immunologic and cell-based regenerative therapies.

Authors:  Martin Friedlander
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

7.  Transplantation of iPSC-derived TM cells rescues glaucoma phenotypes in vivo.

Authors:  Wei Zhu; Oliver W Gramlich; Lauren Laboissonniere; Ankur Jain; Val C Sheffield; Jeffrey M Trimarchi; Budd A Tucker; Markus H Kuehn
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

8.  Human trabecular meshwork cells exhibit several characteristics of, but are distinct from, adipose-derived mesenchymal stem cells.

Authors:  Joshua T Morgan; Joshua A Wood; Naomi J Walker; Vijay Krishna Raghunathan; Dori L Borjesson; Christopher J Murphy; Paul Russell
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-23       Impact factor: 2.671

9.  Efficacy of argon laser trabeculoplasty: 3-year preliminary results of a prospective placebo-controlled study.

Authors:  C Ustundag; M Diestelhorst
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

10.  The effect of argon laser trabeculoplasty on the blood-aqueous barrier and intraocular pressure in human glaucomatous eyes treated with diclofenac 0.1%.

Authors:  M Diestelhorst; D Thull; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.